Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

NCT00736970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms

Interventions

DRUG: ridaforolimus
DRUG: trastuzumab

Sponsor

Merck Sharp & Dohme LLC